<DOC>
	<DOCNO>NCT00135941</DOCNO>
	<brief_summary>The purpose study test superiority improvement baseline patient report outcomes subject type 1 type 2 diabetes treat insulin glargine plus rapid acting insulin glulisine MDI versus treatment premix insulin .</brief_summary>
	<brief_title>Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections ( MDI ) Versus Premix Insulin Treatment Subjects With Diabetes Mellitus ( Type 1 Type 2 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Informed consent write enrollment Subjects type 1 type 2 diabetes mellitus least six month Male female 21 70 year age Employed , unpaid work active lifestyle Screening hemoglobin A1c ( HbA1c ) level ≥ 7.0 ≤ 9.0 % Current ( last 3 month ) daily use premix insulin 75/25 , 70/30 , isophane insulin ( NPH ) Lantus short act insulin , consist 2 injection per day without concomitant therapy consist metformin , thiazolidinedione , and/or alphaglucosidase inhibitor . Willing able inject insulin glargine multiday dose insulin glulisine . Willing able perform selfmonitoring blood glucose ( SMBG ) four time day continuous glucose monitoring ( CGMS ) 48 hour three time period study Willing able use adequate contraception child bear age Able read understand English ( sixth grade level ) comply study protocol Cardiac status New York Heart Association ( NYHA ) IIIIV Serum creatinine ≥ 1.5 mg/dl male , ≥ 1.4 mg/dl female . Clinical evidence active liver disease serum ALT AST &gt; 2.5 time upper limit normal range . Subjects currently use insulin pump Subjects currently take sulfonylurea , repaglinide , nateglinide , symlin ( pramlintide acetate ) byetta ( exenatide ) . Planned pregnancy next 6 month pregnant lactate female Diagnosis dementia mental condition render subject unable understand nature , scope possible consequence study Unable obtain complete CGMS data prior baseline , visit 2 ( week 0 ) Hypersensitivity insulin glargine insulin glulisine premix insulin component Any disease condition ( include abuse illicit drug , prescription medicine alcohol ) opinion investigator sponsor may interfere study compliance completion study . Treatment intermittent dos systemic steroid intermittent large dos inhale steroid past one year ( treatment fix dos past 6 month acceptable providing plan change dosage regimen ) Treatment investigational product last 3 month study entry Stroke , myocardial infarction ( MI ) , coronary artery bypass graft ( CABG ) , percutaneous transluminal coronary angioplasty ( PTCA ) , unstable angina pectoris within last 12 month Current malignancy , previous breast cancer , previous malignant melanoma cancer within past 5 year ( except adequately treat basal cell skin cancer )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
</DOC>